Bexotegrast

• CAT Number: I044658
• CAS Number: 2376257-44-0
• Molecular Formula: C27H36N6O3
• Molecular Weight: 492.61
• Purity: ≥95%
• Synonyms: (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid
• InChI: InChI=1S/C27H36N6O3/c1-36-18-17-33(15-5-4-8-21-12-11-20-7-6-14-28-25(20)31-21)16-13-24(27(34)35)32-26-22-9-2-3-10-23(22)29-19-30-26/h2-3,9-12,19,24H,4-8,13-18H2,1H3,(H,28,31)(H,34,35)(H,29,30,32)/t24-/m0/s1
• InChIKey: CWOFQJBATWQSHL-DEOSSOPVSA-N
• SMILES: COCCN(CCCCC1=NC2=C(CCCN2)C=C1)CC[C@@H](C(=O)O)NC3=NC=NC4=CC=CC=C43

Bexotegrast (Cat No.:I044658) is a selective, oral small-molecule inhibitor of αvβ6 and αvβ1 integrins, key mediators of TGF-β activation. By blocking these integrins, bexotegrast inhibits TGF-β signaling, a central pathway in fibrosis development. It is under clinical investigation for treating fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast reduces extracellular matrix production and tissue scarring, aiming to slow or reverse disease progression. Its dual integrin inhibition profile offers a targeted, anti-fibrotic approach with potential for disease-modifying effects in chronic fibrotic conditions.